Glibenclamide for neonatal diabetes

Indian Pediatrics volume 50, pages 428–429 (2013)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia. 2006;49:1190–1197.
PubMed Article CAS Google Scholar
Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT. Effective treatment with oral sulfonylurea in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 2008;31:204–209.
PubMed Article CAS Google Scholar

Department of Pediatrics and Adolescent Endocrinology, Indraprastha Apollo Hospital, New Delhi, India
IPS Kochar
Department of Endocrinology, Indraprastha Apollo Hospital, New Delhi, India
Radhika Jindal

Authors

IPS Kochar
View author publications
You can also search for this author in PubMed Google Scholar
Radhika Jindal
View author publications
You can also search for this author in PubMed Google Scholar

Correspondence to IPS Kochar.

Kochar, I., Jindal, R. Glibenclamide for neonatal diabetes. Indian Pediatr 50, 428–429 (2013). https://doi.org/10.1007/s13312-013-0106-0